We are live on ! Find out more
NKGN

NKGen Biotech, Inc. Common Stock
NKGN

Delisted

NKGN was delisted on the 4th of March, 2025.

Back to rankings

48 hedge funds and large institutions have $123M invested in NKGen Biotech, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

12% more funds holding

Funds holding: 43 → 48 (+5)

6% more capital invested

Capital invested by funds: $117M → $123M (+$6.72M)

Holders
48
Holders Change
+5
Holders Change %
+11.63%
% of All Funds
0.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
4
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
+$3.43M
2
CSS
Cubist Systematic Strategies
Connecticut
+$3.23M
3
CF
Cantor Fitzgerald
New York
+$2.48M
4
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$1.6M
5
EAM
Exos Asset Management
New York
+$700K

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$3.39M
2
SG
StoneX Group
New York
-$97K
3
HighTower Advisors
HighTower Advisors
Illinois
-$3.16K
Name Holding Trade Value Shares
Change 		Change in
Stake
SG
51
StoneX Group
New York
– -$97K -10,000 Closed
1 2
3

NKGN Hedge Fund Activity: Q2 2022 in Review

48 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q2 2022, worth a combined $123M — up 5.8% from $117M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new NKGN positions and 3 closed out — a net gain of 6 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was UBS O'Connor, opening a new position worth an estimated $3.43M. The largest seller was Bank of America, exiting entirely with an estimated $3.39M sold.

  • 48 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q2 2022, up from 43 in Q1 2022.
  • Funds reported $123M of NKGen Biotech, Inc. Common Stock stock for Q2 2022, up 5.8% quarter-over-quarter.
  • 9 funds opened new NKGen Biotech, Inc. Common Stock positions in Q2 2022 and 3 closed out, a net change of +6 holders.
  • The largest NKGen Biotech, Inc. Common Stock buyer in Q2 2022 was UBS O'Connor, an estimated $3.43M added.
  • The largest NKGen Biotech, Inc. Common Stock seller in Q2 2022 was Bank of America, an estimated $3.39M sold.

Based on aggregated 13F filings for Q2 2022.